探究氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床价值

Exploration on the Clinical Value of Amlodipine and Atorvastatin Calcium Tablets in the Treatment of Hypertension with Coronary Heart Disease

目的分析氨氯地平阿托伐他汀钙片(ABAACT)治疗高血压(HBP)合并冠心病(CHD)的效果。方法该研究主体为方便选取2017年2月—2020年1月间来该院治疗的85例HBP+CHD患者。以硬币法为标准,A组43例行ABAACT治疗,B组42例行阿托伐他汀钙片(ACT)治疗,对比整体疗效。结果A组的总有效率(95.35%)高于B组(78.57%),差异有统计学意义(χ^(2)=5.308,P=0.021)。A组的舒张压(DBP)(83.57±4.51)mmHg低于B组的(92.34±4.61)mmHg(t=8.866,P<0.001);A组的收缩压(SBP)(123.68±10.33)mmHg低于B组的(134.18±10.57)mmHg,差异有统计学意义(t=4.632,P<0.001);A组的总胆固醇(TC)(4.31±0.81)mmol/L低于B组(5.77±0.95)mmol/L,差异有统计学意义(t=7.631,P<0.001);高密度脂蛋白(HDL-C)(3.28±0.34)mmol/L高于B组(2.71±0.28)mmol/L(t=8.426,P<0.001);A组的甘油三酯(TG)(3.31±0.50)mmol/L低于B组(4.09±0.58)mmol/L,差异有统计学意义(t=6.646,P<0.001);A组的低密度脂蛋白(LDL-C)(1.33±0.72)mmol/L低于B组(1.69±0.78)mmol/L,差异有统计学意义(t=2.212,P=0.030)。A组的不良反应率(4.65%)低于B组(19.05%),差异有统计学意义(χ^(2)=4.242,P=0.039)。结论为该合并症患者行ABAACT治疗可优化血压、血脂水平,减少不良反应,疗效显著。

Objective To analyze the effect of amlodipine and atorvastatin calcium tablets(ABAACT)in the treatment of hypertension(HBP)combined with coronary heart disease(CHD).Methods The subject of this study was convenient to select 85 patients with HBP+CHD who came to the hospital for treatment from February 2017 to January 2020.Taking the coin method as the standard,43 patients in group A were treated with ABAACT,and 42 patients in group B were treated with atorvastatin calcium tablets(ACT).The overall efficacy was compared.Results The total effective rate of group A(95.35%)was higher than that of group B(78.57%),the difference was statistically significant(χ^(2)=5.308,P=0.021).The diastolic blood pressure(DBP)(83.57±4.51)mmHg of group A was lower than that of group B(92.34±4.61)mmHg,the difference was statistically significant(t=8.866,P<0.001);the systolic blood pressure(abbreviated as SBP)of group A(123.68±10.33)mmHg was lower than(134.18±10.57)mmHg in group B,the difference was statistically significant(t=4.632,P<0.001);total cholesterol(TC for short)(4.31±0.81)mmol/L in group A was lower than group B(5.77±0.95)mmol/L,the difference was statistically significant(t=7.631,P<0.001);high density lipoprotein(HDL-C for short)(3.28±0.34)mmol/L was higher than group B(2.71±0.28)mmol/L,the difference was statistically significant(t=8.426,P<0.001);Triglycerides(TG)(3.31±0.50)mmol/L in group A were lower than those in group B(4.09±0.58)mmol/L,the difference was statistically significant(t=6.646,P<0.001);low-density lipoprotein(TG for short)in group A(LDL-C for short)(1.33±0.72)mmol/L was lower than group B(1.69±0.78)mmol/L,the difference was statistically significant(t=2.212,P=0.030).The adverse reaction rate of group A(4.65%)was lower than that of group B(19.05%),the difference was statistically significant(χ^(2)=4.242,P=0.039).Conclusion ABAACT treatment for patients with this comorbidity can optimize blood pressure and blood lipid levels,reduce adverse reactions,and have a significant effect.